New prognostic markers for colon cancer identified

November 11, 2020

The gut-associated lymphoid tissue represents an integral part of the immune system. Among the powerful players of the mucosa-associated lymphoid tissue are isolated lymphoid structures (ILSs). Additionally, in the course of cancer, ectopic lymphoid structures (ELSs; also known as tertiary lymphoid structures, TLSs) were shown to be formed at the tumor site. Both ILSs and ELSs act as multitasking information centers triggering multifaceted immune responses. An in-depth understanding of the complexity and functionality of ILSs and ELSs may lead to new directions in therapeutic interventions and/or provide help in treatment decisions as part of personalized medicine. The study recently published by researchers from MedUni Vienna and collaborative partners nominates ILSs as novel prognostic players orchestrating the pathobiology of metastatic colorectal cancer.

Cumulative data within the rapidly evolving field of immuno-oncology positions tumor infiltrating B cells among powerful contributors to anti-tumor immunity. One essential aspect that links the B-cell biology, the adaptive immunity, and the inflammation process to the tumor microenvironment is based on the unique ability of B cells to form ELSs. Central to this are Germinal Center reactions, which involve the coordinated action of various immune cell types with a central role given to B cells.

Key information that needs to be considered for understanding the ELSs in solid tumors is that there are tissue types where such lymphoid structures are physiologically appearing to fulfil an important balance between effective and protective immune response and self-tolerance. "This holds true for organs with specialized immunity at epithelial barriers. Among those is the gut-associated lymphoid tissue with the ILSs being among the most powerful players." saysDiana Mechtcheriakova, principal investigator and the head of Molecular Systems Biology and Pathophysiology Research Group at the Institute of Pathophysiology and Allergy Research, Medical University of Vienna. "We aimed to investigate whether there is a link between the patient-specific characteristics of pre-formed isolated lymphoid structures in non-tumorous colon tissue and the disease pathobiology for patients with metastatic colorectal cancer."

In this study the multidisciplinary research team implemented newly developed integrative strategy named DIICO/from Digital Immune Imaging to Clinical Outcome. DIICO is based on digital tissue image cytometry which enables to transform encrypted tissue information on immune cells and structures into numerical data for alignment with disease-relevant parameters. Important additive information was obtained by B-cell clonality assessment and a comprehensive analysis of Omics data..

The authors showed that the properties of ILSs in non-tumorous colon tissue predefine the immune phenotype of ELSs at primary and metastatic sites. They discovered that B-cell-enriched and highly proliferative lymphoid structures are prognostic towards an improved clinical outcome for patients with metastatic CRC. The knowledge gained from this study expands our understanding of tumor-immune interactions and draws particular attention to the anti-tumor immune response guided by isolated lymphoid structures outside of tumor tissue.

Medical University of Vienna

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to